Work

41602 Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to- head clinical trials

Year: 2023

Type: article

Source: Journal of the American Academy of Dermatology

DOI: 10.1016/j.jaad.2023.07.056

Authors: April Armstrong, Andrew Blauvelt, Kim A. Papp, Lawrence J. Green, Meghan Feely, William N. Malatestinic, Kyoungah See, Missy McKean-Matthews, Bruce E. Strober

Institutions: University of Southern California, Oregon Medical Research Center, Probity Medical Research, George Washington University, Eli Lilly (United States), Syneos Health (United States), Yale University

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4387031179

FWCI:

Cites:

Cited by:

Related to: 10